Drug
BCMA Targeted CAR T-cells
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph early_phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
3(100.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Not yet recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 13 (100.0%)
Trials by Status
unknown133%
not_yet_recruiting267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1
Study of SYS6020 in BCMA-positive Multiple Myeloma
NCT06359509
unknownearly_phase_1
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT05430945
not_yet_recruitingearly_phase_1
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT04670055
Clinical Trials (3)
Showing 3 of 3 trials
NCT06359509Early Phase 1
Study of SYS6020 in BCMA-positive Multiple Myeloma
NCT05430945Early Phase 1
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT04670055Early Phase 1
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3